2020 American Transplant Congress
Induction Immunosuppression with Thymoglobulin May Improve Graft Outcomes without Increasing a Risk for Infection in Patients Undergoing Liver Transplantation Alone
*Purpose: Immunosuppression protocols for liver transplant (LT) vary between institutions and roles of induction immunosuppression in LT remain controversial. The aim of this study was…2020 American Transplant Congress
Basiliximab vs Antithymocyte Globulin Induction with Early Steroid Withdrawal in Kidney Transplant Recipients: Early Rejection Outcomes
*Purpose: Steroid withdrawal within the first month of kidney transplant (KT) remains controversial and has demonstrated a higher risk of acute rejection. The impact of…2020 American Transplant Congress
Evaluation of Leukopenia and Neutropenia Incidence, Treatment, and Clinical Response in Kidney and Liver Transplant Recipients
Hartford Hospital, Hartford, CT
*Purpose: The purpose is to evaluate incidence, recurrence, therapy modifications, and complications of leukopenia and neutropenia (LN) in kidney (KTR) and liver transplant (LTR) recipients.*Methods:…2020 American Transplant Congress
Recruitment in the Pediatric Heart Transplant TEAMMATE Trial: Observed vs. Expected
TEAMMATE Trial Investigators, Boston, MA
*Purpose: The TEAMMATE (Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients using the MATE Score) Trial is the first multicenter effort to address key scientific…2020 American Transplant Congress
De Novo Use of Envarsus (LCPT) in African American and Elderly Kidney Transplant Recipients: An Early Single Center Experience
*Purpose: Clinical trials with LCPT have shown a steadier and more consistent concentration time profile over 24 hours with increased bioavailability compared to twice daily…2020 American Transplant Congress
Granulocyte-Colony Stimulating Factor (G-CSF) and Granulocyte-Macrophage CSF (GM-CSF) Administration Enriches for Highly Suppressive CD4+CD45RA–Foxp3hi Cells in Leukapheresis Products of Rhesus Monkeys
Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA
*Purpose: In humans, CD4+CD45RA-Foxp3hi T cells comprise a regulatory T cell (Treg) subset with highly suppressive function. We have previously shown that granulocyte-colony stimulating factor…2020 American Transplant Congress
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the…2020 American Transplant Congress
Challenges in Manufacturing Clinically Competent Regulatory T Cells from Obese Renal Transplant Recipients
Surgery, University of Kentucky, Lexington, KY
*Purpose: The obesity epidemic has expanded rapidly over the last decade. Our program is developing a novel clinical protocol using expanded autologous regulatory T cell…2020 American Transplant Congress
A Multicenter, Randomized, Controlled Trial to Steer Immunosuppressive Therapy by Virus-Specific T Cells after Pediatric Kidney Transplantation (IVIST-Trial)
*Purpose: Pharmakokinetic monitoring of immunosuppressants alone is insufficient to estimate the individual intensity of immunosuppression after kidney transplantation (Tx). Virus-specific T cells (Tvis) correlate with…2020 American Transplant Congress
Belatacept Conversion: Are Patients BENEFIT-ing
Columbia University Irving Medical Center, New York, NY
*Purpose: Belatacept is increasingly used in renal transplant recipients experiencing adverse effects from calcineurin inhibitors(CNI) despite limited medium- and long- term data on safety and…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 138
- Next Page »